JP4395368B2 - 細胞殺傷活性を有するカルシウム塩 - Google Patents
細胞殺傷活性を有するカルシウム塩 Download PDFInfo
- Publication number
- JP4395368B2 JP4395368B2 JP2003511837A JP2003511837A JP4395368B2 JP 4395368 B2 JP4395368 B2 JP 4395368B2 JP 2003511837 A JP2003511837 A JP 2003511837A JP 2003511837 A JP2003511837 A JP 2003511837A JP 4395368 B2 JP4395368 B2 JP 4395368B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- tumor
- trifluoroacetate
- cell killing
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
[マウスおよびラットにおける毒性]
腹腔内経路によりBalb/cマウスに急性投与量200mg/kgで投与されるトリフルオロ酢酸カルシウムは、注目に値する毒性効果を全く示さない。
トリフルオロ酢酸カルシウムの細胞殺傷性が、ヒト悪性腫瘍の細胞株13個と良性腫瘍の細胞株4個で決定された。
異なる組織型および起源のヒト悪性細胞株によって、トリフルオロ酢酸カルシウムに対する細胞毒性反応が、用量によるが様々な細胞株間で異なり、常に非常に高い細胞死レベルに達することが実証されている:8/14が死滅率100%に達し、6/14が範囲80%〜90%の値に達した。
[実験用マウスの腫瘍]
Balb/Cマウスに、C26(マウスの結腸腺癌)の25,000細胞/マウスを接種した。
家畜、特にイヌにおける自然発生腫瘍について行われる実験は、ヒトにおける活性が予測される信頼性のあるモデルであるとみなされている(D. M Vail et al., Spontaneously occurring tumors in companion animals as models for drug development. Anticancer drug development guide: preclinical screening, clinical trials and approval. Edited by B. Teicher Humana Press Inc. , Totowa, NJ)。
[臨床ケース]
進行している疾患状態の、かつ拡散転移している、乳癌(3ケース),大腸癌(3ケース)および子宮ガン(1ケース)の56〜63才の患者5名に範囲10〜200mgの投与量で、トリフルオロ酢酸カルシウムを皮下投与した。疾患状態が高度に進行していたために、患者が死に至った大腸癌の1ケースを除いては(明らかな倫理的理由から、同情的プロトコルに基づいて、すべてのケースを処置した)、治療反応は、客観的面(腫瘍塊の約10〜40%の減少、腹水および転移性リンパ節の減少および消失、およびCA19.9およびα−フェトプロテインなどの腫瘍マーカーの減少)、と主観的面(気分の改善、痛みの減少および消失、および仕事および社会生活への復帰)のどちらにおいても、驚くべきものであった。死亡した患者のケースでさえ、癌性悪液質および心肺合併症が悪化したために死亡したが、腫瘍塊の減少が認められた。
Claims (3)
- 抗腫瘍剤を製造するためのトリフルオロ酢酸カルシウムの使用。
- 活性成分としてトリフルオロ酢酸カルシウムを含有する抗腫瘍剤組成物。
- さらに賦形剤を含む請求項2の組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2001MI001495A ITMI20011495A1 (it) | 2001-07-12 | 2001-07-12 | Sali di calcio ad attivita' citotossica |
PCT/EP2002/007222 WO2003006031A1 (en) | 2001-07-12 | 2002-07-01 | Calcium salts with cytotoxic activity |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004536120A JP2004536120A (ja) | 2004-12-02 |
JP4395368B2 true JP4395368B2 (ja) | 2010-01-06 |
Family
ID=11448051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003511837A Expired - Fee Related JP4395368B2 (ja) | 2001-07-12 | 2002-07-01 | 細胞殺傷活性を有するカルシウム塩 |
Country Status (10)
Country | Link |
---|---|
US (1) | US7423063B2 (ja) |
EP (1) | EP1423131B1 (ja) |
JP (1) | JP4395368B2 (ja) |
AT (1) | ATE345805T1 (ja) |
CA (1) | CA2455710C (ja) |
DE (1) | DE60216292T2 (ja) |
ES (1) | ES2277620T3 (ja) |
IL (2) | IL159770A0 (ja) |
IT (1) | ITMI20011495A1 (ja) |
WO (1) | WO2003006031A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20040665A1 (it) * | 2004-04-02 | 2004-07-02 | Pharmaproducts Uk Ltd | Sale di calcio per il trattamento della psoriasi e di dermatiti |
ITMI20041279A1 (it) * | 2004-06-24 | 2004-09-24 | Pharmaproducts Uk Ltd | Uso di calcio trifluoroacetato per la preparazione di medicamenti ad effetto anti-angiogenetico |
ITMI20041822A1 (it) * | 2004-09-24 | 2004-12-24 | Pharmaproducts Uk Ltd | "agente terapeutico utile per il trattamento di neoplasie plasmacellulari" |
EP2796135A1 (en) | 2013-04-22 | 2014-10-29 | Polichem S.A. | Use of trifluoroacetic acid and salts thereof to treat hypercholesterolemia |
EP2845591A1 (en) | 2013-09-04 | 2015-03-11 | Polichem S.A. | Use of trifluoroacetic acid as keratolytic agent to treat hyperkeratotic skin lesions |
KR101683635B1 (ko) | 2014-12-29 | 2016-12-09 | 가천대학교 산학협력단 | 락테이트 금속염을 포함하는 암 치료용 약학 조성물 |
EA202091446A1 (ru) | 2018-01-12 | 2021-01-29 | Метимеди Фармасьютикалз Ко., Лтд. | Способы лечения хронических воспалительных заболеваний |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4636564A (en) * | 1984-11-13 | 1987-01-13 | Board Of Trustees Of The University Of Alabama | 5-cyanopyridine-2-diazohydroxide, basic salts and methods for production and use |
US4880660A (en) * | 1987-08-28 | 1989-11-14 | Minnesota Mining And Manufacturing Company | Method for priming hard tissue |
US5250545A (en) * | 1988-02-12 | 1993-10-05 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitor methods |
UA32427C2 (uk) * | 1993-10-15 | 2000-12-15 | Елі Ліллі Енд Компані | Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань |
US5593987A (en) * | 1993-12-21 | 1997-01-14 | Eli Lilly And Company | Methods of inhibiting breast disorders |
US5639787A (en) * | 1995-02-28 | 1997-06-17 | The Center For The Improvement Of Human Functioning Int'l, Inc. | Therapeutic method for the treatment of cancer |
-
2001
- 2001-07-12 IT IT2001MI001495A patent/ITMI20011495A1/it unknown
-
2002
- 2002-07-01 US US10/483,285 patent/US7423063B2/en not_active Expired - Fee Related
- 2002-07-01 IL IL15977002A patent/IL159770A0/xx unknown
- 2002-07-01 AT AT02764607T patent/ATE345805T1/de active
- 2002-07-01 EP EP02764607A patent/EP1423131B1/en not_active Expired - Lifetime
- 2002-07-01 JP JP2003511837A patent/JP4395368B2/ja not_active Expired - Fee Related
- 2002-07-01 ES ES02764607T patent/ES2277620T3/es not_active Expired - Lifetime
- 2002-07-01 CA CA2455710A patent/CA2455710C/en not_active Expired - Fee Related
- 2002-07-01 DE DE60216292T patent/DE60216292T2/de not_active Expired - Lifetime
- 2002-07-01 WO PCT/EP2002/007222 patent/WO2003006031A1/en active IP Right Grant
-
2004
- 2004-01-08 IL IL159770A patent/IL159770A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2003006031A1 (en) | 2003-01-23 |
EP1423131B1 (en) | 2006-11-22 |
ATE345805T1 (de) | 2006-12-15 |
DE60216292D1 (de) | 2007-01-04 |
IL159770A0 (en) | 2004-06-20 |
US7423063B2 (en) | 2008-09-09 |
JP2004536120A (ja) | 2004-12-02 |
CA2455710A1 (en) | 2003-01-23 |
ITMI20011495A0 (it) | 2001-07-12 |
ES2277620T3 (es) | 2007-07-16 |
US20040180956A1 (en) | 2004-09-16 |
ITMI20011495A1 (it) | 2003-01-12 |
DE60216292T2 (de) | 2007-08-30 |
EP1423131A1 (en) | 2004-06-02 |
CA2455710C (en) | 2012-08-28 |
IL159770A (en) | 2009-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH01226810A (ja) | 悪性腫瘍を破壊する作用を有する剤、その製造方法及び癌疾患の治療に使用する調製物 | |
JP2004530659A (ja) | 抗腫瘍および抗転移作用のための方法および処方 | |
JP4395368B2 (ja) | 細胞殺傷活性を有するカルシウム塩 | |
WO2022068918A1 (zh) | 包含酸碱中和组合的药物组合物及其应用 | |
US4384001A (en) | Treatment of tumors with thiazolidine-4-carboxylic acid | |
AU776732B2 (en) | Pharmaceutical compositions containing copper, salicylic acid and vitamines C | |
JPH06503806A (ja) | 胃腸疾病を処置するための5―ジフルオロメトキシ―2―[(3,4―ジメトキシ―2―ピリジル)メチルスルフィニル]ベンズイミダゾール及び抗ヘリコバクター剤含有医薬組成物 | |
JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および/または症状軽減剤 | |
JPS6310728A (ja) | ジサツカライド誘導体含有鎮痛剤 | |
JP2020537689A (ja) | A−ノル−5αアンドロスタン化合物を含む白血球増多製剤およびその使用 | |
Collier et al. | Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma | |
JP4707668B2 (ja) | オキソプラチン、その塩および誘導体を含む医薬組成物 | |
CA2576926A1 (en) | Use of midostaurin for treating gastrointestinal stromal tumors | |
JP2004504346A (ja) | 骨転移の治療におけるリン酸エストラムスチンの使用 | |
CN106038566B (zh) | 一种用于胃癌治疗的药物组合物及其应用 | |
JPH059116A (ja) | 3−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤 | |
RU2211035C1 (ru) | Противотуберкулезный препарат | |
Chomczynski et al. | Compositions and methods for anti-inflammatory treatments | |
CN106668061B (zh) | 一种含有顺铂的抗癌药物组合物 | |
JP3662016B2 (ja) | 便秘及び便秘に伴う症状の予防及び/又は治療のための医薬 | |
JP2001514671A (ja) | 癌治療薬 | |
JPH08165236A (ja) | 下痢の予防及び治療剤 | |
JP2021521189A (ja) | 脱髄の治療のための組成物及び方法 | |
RU2280457C1 (ru) | Лекарственное средство для лечения железодефицитных анемий | |
CN110327327A (zh) | 一种用于治疗骨折术后坠积性肺炎的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050614 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050713 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060210 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070621 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090507 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091006 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091019 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121023 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121023 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121023 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121023 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131023 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |